Data from multiple sources - Curated by Marshall Pearce - Last updated 06 June 2017

Latest news articles

Added 2 months ago Drug news

Post hoc analysis of two trials of Krystexxa show reductions in blood pressure in gout patients.- HorizonPharma.

Horizon Pharma plc presented a post-hoc analysis of data from two randomized, placebo-controlled clinical trials of Krystexxa (pegloticase injection) in...

Added 4 months ago Drug news

FDA approves Duzallo (lesinurad + allopurinol) to treat hyperuricemia associated with gout.- Ironwood Pharma

Ironwood Pharmaceuticals, Inc.has announced Duzallo (lesinurad + allopurinol) was approved by the FDA as a once-daily oral treatment for hyperuricemia...

Added 7 months ago Drug news

UK's NICE rejects use of Zurampic (febuxostat + lesinurad) in gout- Gruenenthal

The National Institute for Health and Care Excellence has published draft guidelines preventing adults with gout from access to Zurampic...

Search all news articles for Gout
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

IL-17A in Psoriasis

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress.

+ 1 more

Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

+ 2 more

Load more

Journal articles

Lesinurad: A Review in Hyperuricaemia of Gout.

Lesinurad (Zurampic®) is an oral selective inhibitor of the URAT1 and OAT4 uric acid (UA) transporters of the kidney, via which it inhibits UA reabsorption and thus increases renal UA excretion and lowers serum UA (sUA) levels.

Added 7 months ago

Lesinurad: A significant advancement or just another addition to existing therapies of gout?

Gout is a metabolic disorder that usually presents as recurrent episodes of acute arthritis due to deposition of crystals in joints and cartilages. Despite the availability of several drugs for gout, its management is still less than adequate.

Added 7 months ago

Use of febuxostat in the management of gout in the United Kingdom.

Gout is the most common cause of inflammatory arthritis worldwide. Despite clinical cure being achievable and multiple evidence-based guidelines having been published, the incidence and prevalence continues to increase ...

Added 8 months ago

Search all journal articles for Gout
 

Clinical trials

Combining Lesinurad With Allopurinol in Inadequate Responders (CLEAR 1)

This study that compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to allopurinol.

Added 7 years ago

Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat (CRYSTAL)

This study will compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with febuxostat...

Added 7 years ago

Combining Lesinurad With Allopurinol in Inadequate Responders (CLEAR 2)

This study will compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to allopurinol.

Added 7 years ago

Search all clinical trials for Gout